慢性肝病中的炎症小体:肝损伤、纤维化进展与全身性炎症
本综述概述炎症小体在慢性肝病进展中的激活机制,涉及固有免疫细胞通过Toll样受体和NF-κB激活细胞内在炎症小体并释放IL-1β、IL-18、TNF-α和IL-6等促炎细胞因子,进而招募适应性免疫细胞、诱导gasdermin D介导的细胞焦亡,随疾病进展向2型炎症反应偏移促进组织修复和纤维化,肝外部位如MASH的白脂肪组织也可发生炎症小体激活,终末期肝病中炎症 flares 在功能障碍免疫系统上触发炎症小体介导的肝损伤并可能导致ACLF中的器官功能障碍/衰竭,文章重点讨论相关生物标志物和正在开发的治疗方法。
要点
- 炎症小体是肝损伤的关键分子驱动因素,可能促成新型诊断或预后生物标志物及有效治疗方法的开发。
- 肝病进展中炎症反应向2型偏移,既促进组织修复也促进纤维化。
- MASH的白脂肪组织等肝外部位也可发生炎症小体激活,严重酒精相关肝炎等终末期肝病的炎症 flares 可导致ACLF样器官功能障碍/衰竭。
核心结论
- 更好地理解炎症小体作为肝损伤的关键分子驱动因素,可能促成新型诊断或预后生物标志物及有效治疗方法的开发。
研究设计与样本
- 综述,概述当前关于炎症小体在肝病进展中激活的概念,重点讨论相关生物标志物和正在为肝病患者开发的治疗方法。
主要发现
- 固有免疫细胞通过Toll样受体和NF-κB激活细胞内在炎症小体,并释放IL-1β、IL-18、TNF-α和IL-6等促炎细胞因子。
- 随后招募适应性免疫系统细胞加剧肝脏炎症,肝实质细胞可发生gasdermin D介导的程序性细胞死亡即细胞焦亡。
- 随着肝病进展,炎症反应向2型偏移,促进组织修复但也促进纤维化。
- 炎症小体激活也可发生在肝外部位,如MASH的白脂肪组织。
- 终末期肝病中,在功能障碍免疫系统上触发的炎症 flares(如严重酒精相关肝炎)促进炎症小体介导的肝损伤,并可能导致ACLF中所见的器官功能障碍/衰竭。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic liver disease leads to hepatocellular injury that triggers a pro-inflammatory state in several parenchymal and non-parenchymal hepatic cell types, ultimately resulting in liver fibrosis, cirrhosis, portal hypertension and liver failure. Thus, an improved understanding of inflammasomes - as key molecular drivers of liver injury - may result in the development of novel diagnostic or prognostic biomarkers and effective therapeutics. In liver disease, innate immune cells respond to hepatic insults by activating cell-intrinsic inflammasomes via toll-like receptors and NF-κB, and by releasing pro-inflammatory cytokines (such as IL-1β, IL-18, TNF-α and IL-6). Subsequently, cells of the adaptive immune system are recruited to fuel hepatic inflammation and hepatic parenchymal cells may undergo gasdermin D-mediated programmed cell death, termed pyroptosis. With liver disease progression, there is a shift towards a type 2 inflammatory response, which promotes tissue repair but also fibrogenesis. Inflammasome activation may also occur at extrahepatic sites, such as the white adipose tissue in MASH (metabolic dysfunction-associated steatohepatitis). In end-stage liver disease, flares of inflammation (e.g., in severe alcohol-related hepatitis) that spark on a dysfunctional immune system, contribute to inflammasome-mediated liver injury and potentially result in organ dysfunction/failure, as seen in ACLF (acute-on-chronic liver failure). This review provides an overview of current concepts regarding inflammasome activation in liver disease progression, with a focus on related biomarkers and therapeutic approaches that are being developed for patients with liver disease.
引用
- Taru V, Szabo G, Mehal W, et al. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024. PMID: 38908436. doi:10.1016/j.jhep.2024.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。